References
- Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165–182. doi:10.1001/jama.2016.19043
- Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1345–1422. doi:10.1016/S0140-6736(17)32366-8
- Lewington S, Lacey B, Clarke R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med. 2016;176:524–532. doi:10.1001/jamainternmed.2016.0190
- Zhou B, Bentham J, Cesare MD, et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017;389:37–55. doi:10.1016/S0140-6736(16)31919-5
- Wang J, Zhang L, Wang F, Liu L, Wang H; China National Survey of Chronic Kidney Disease Working G. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014;27:1355–1361. doi:10.1093/ajh/hpu053
- Fang L, Song J, Ma Z, Zhang L, Jing C, Chen D. Prevalence and characteristics of hypertension in mainland Chinese adults over decades: a systematic review. J Hum Hypertens. 2014;28:649–656. doi:10.1038/jhh.2014.5
- Ke Y, Zhu D, Hong H, et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin. 2010;26:1705–1713. doi:10.1185/03007995.2010.487391
- Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390:2549–2558. doi:10.1016/S0140-6736(17)32478-9
- Kintscher U. The burden of hypertension. EuroIntervention. 2013;9(Suppl R):R12–R15. doi:10.4244/EIJV9SRA3
- Wang Y, Peng X, Nie X, et al. Burden of hypertension in China over the past decades: systematic analysis of prevalence, treatment and control of hypertension. Eur J Prev Cardiol. 2016;23:792–800. doi:10.1177/2047487315617105
- Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003–1010. doi:10.1001/jama.287.8.1003
- Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3:999–1005.
- Le C, Zhankun S, Jun D, Keying Z. The economic burden of hypertension in rural south-west China. Trop Med Int Health. 2012;17:1544–1551. doi:10.1111/tmi.2012.17.issue-12
- Lee JH, Kim SH, Kang SH, et al. Blood pressure control and cardiovascular outcomes: real-world implications of the 2017 ACC/AHA hypertension guideline. Sci Rep. 2018;8:13155. doi:10.1038/s41598-018-31549-5
- Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116:1074–1095. doi:10.1161/CIRCRESAHA.116.303603
- Gorostidi M, de la Sierra A. Combination therapies for hypertension - why we need to look beyond RAS blockers. Expert Rev Clin Pharmacol. 2018;11:841–853. doi:10.1080/17512433.2018.1509705
- Revision Committee of Clinical Practice Guidelines for the Management of Hypertention in the Community. Clinical practice guidelines for the management of hypertension in the community. Chin J Health Manage. 2015;9:20.
- Committee of Expert on Hypertention Management in Community. Clinical practice guidelines for the prevention and management of hypertension in the community. Chin Circul J. 2017;32:8.
- Comittee of Experts on Rational Drug Use,National Health and Family Planning Commission of the P.R.China. Clinical practice guidelines for hypertension rational drug use. Chin J Front Med Sci. 2017;9:98.
- Chinese Hypertention Committee of the Chinese Medical Doctors Association. Chinese expert consensus on clinical application of compound reserpine and triamterene tablets. Chin J Hypertens. 2016;24:945.
- Wang Hongyi SN, Shan J, Yuanyuan C, Luyan W. Efficacy and safety of reserpine and triamterene compound tablets and indapamide inpatients with essential hypertension: a randomized controlled clinical study. Chin J Hypertens. 2016;24:6.
- Wu YQ, Hu YH, Ren T, et al. Cost-effectiveness analysis on compound anti-hypertensive tablets for primary hypertension. Chin J Epidemiol. 2008;29:4.